Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer

Wolfgang Janni, MD, PhD
Published: Tuesday, Apr 04, 2017



Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.

The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.
 


Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.

The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Publication Bottom Border
Border Publication
x